Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANCILE-30: C7R.CD30-CAR-EBVSTs for CD30 Lymphoma
NCT07729397Phase 1Not yet recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jan 2027
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous C7R.CD30-CAR-EBVSTs in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL) and 1 more, sponsored by Houston Methodist Research Institute. Primary endpoint: Incidence of Dose-Limiting Toxicities at 28 days. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
autologous C7R.CD30-CAR-EBVSTs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT07729397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729397.